AVDL
NASDAQ
IE
Avadel Pharmaceuticals plc - Ordinary Share
$21.64
+0.0 (+0.0%)
7
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$2.1B
ROE
-0.3%
Margin
-0.1%
D/E
35.46
Beta
1.36
52W
$6–$24
Wall Street Consensus
16 analysts · Apr 20262
Strong Buy
4
Buy
10
Hold
0
Sell
0
Strong Sell
37.5%
Buy Rating
Price Chart
Similar Stocks
About Avadel Pharmaceuticals plc - Ordinary Share
AVDL - це фармацевтична компанія, що спеціалізується на розробці та виробництві генеричних лікарських засобів та активних фармацевтичних інгредієнтів. Компанія займає стабільну позицію на ринку завдяки широкому асортименту продукції та конкурентним цінам. Її ключова перевага - це здатність швидко виводити на ринок доступні аналоги відомих препаратів.
Earnings
Beat rate: 50.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Sep 2025 | $0.07 | $0.00 | $-0.07 |
| Jun 2025 | $0.03 | $0.10 | +$0.07 |
| Mar 2025 | $-0.07 | $-0.05 | +$0.02 |
| Dec 2024 | $-0.04 | $-0.05 | $-0.01 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… |
|---|---|---|---|---|---|
| Revenue | $50.0M | $50.4M | $52.5M | $68.1M | $77.5M |
| Net Income | -$2.6M | -$5.0M | -$4.9M | $9.7M | $20K |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -3.7% | -3.7% | -3.7% | -3.7% | -0.3% | -0.3% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | 14.2% | -1.3% | -1.3% | -1.3% | -0.1% | -0.1% |
| Gross Margin | 90.7% | 89.6% | 89.6% | 89.6% | 91.1% | 91.1% |
| D/E Ratio | 38.94 | 0.00 | 0.00 | 0.00 | 35.46 | 35.46 |
| Current Ratio | 2.79 | 2.79 | 2.79 | 2.79 | 2.76 | 2.76 |
Key Ratios
ROA (TTM)
-0.2%
P/S (TTM)
8.48
P/B
13.7
EPS (TTM)
$-0.01
CF/Share
$-2.14
Rev Growth 3Y
+96.4%
52W High
$23.57
52W Low
$6.38
$6.38
52-Week Range
$23.57
Financial Health
Free Cash Flow
$7.2M
Net Debt
-$77.3M
Cash
$79.8M
Total Debt
$2.5M
As of Sep 30, 2025
How does AVDL compare to Pharmaceuticals peers?
Peer group: Mid-cap Pharmaceuticals ($2B+) · 25 companies
AVDL valuation vs Pharmaceuticals peers
P/E ratio
—
▼
0%
below
peers
(30.7)
vs Peers
vs Industry
Fair value
P/S ratio
8.5
▲
26%
above
peers
(6.7)
vs Peers
vs Industry
Pricier
P/B ratio
13.7
▲
163%
above
peers
(5.2)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(3.1%)
vs Peers
vs Industry
Low yield
AVDL profitability vs Pharmaceuticals peers
ROE
-0.3%
▲
99%
above
peers
(-26.1%)
vs Peers
vs Industry
Below avg
Net margin
-0.1%
▲
92%
above
peers
(-1.5%)
vs Peers
vs Industry
Below avg
Gross margin
91.1%
▲
2%
above
peers
(88.9%)
vs Peers
vs Industry
In line
ROA
-0.2%
▲
98%
above
peers
(-9.5%)
vs Peers
vs Industry
Below avg
AVDL financial health vs Pharmaceuticals peers
D/E ratio
35.5
▲
30%
above
peers
(27.4)
vs Peers
vs Industry
Above avg
Current ratio
2.8
▼
21%
below
peers
(3.5)
vs Peers
vs Industry
Below avg
Beta
1.4
▲
130%
above
peers
(0.6)
vs Peers
vs Industry
More volatile
AVDL fundamentals radar
AVDL
Peer median
Industry
AVDL profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
AVDL vs peers: key metrics
Insider Activity
NeutralBuys
0
Sells
0
MCCAMISH MARK ANTHONY
Director · Feb 04
67025 shs
Last 90 days
Top Holders
Top 5: 15.35%Blackrock Inc.
7.17%
$152.4M
Vanguard Group Inc
5.98%
$126.9M
Geode Capital Management, L…
2.20%
$46.7M
As of Dec 31, 2025
Latest News
No related news yet